Argireline (acetyl Hexapeptide-3)
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Argireline is the best-known and longest-marketed of the “topical Botox” peptide family — a hexapeptide formulated into serums and creams as a topical alternative to injectable neuromodulators for softening expression lines (forehead lines, crow’s feet, frown lines).
What does it do in my body?
Argireline competes with SNAP-25 for its position in the SNARE complex, the molecular machinery that docks neurotransmitter vesicles at the neuromuscular junction. By displacing SNAP-25, it reduces vesicle docking and acetylcholine release, so the muscle contracts less intensely — the same target signal that botulinum toxin blocks at the muscle, approached from a topical serum instead of an injection.
How can it help me?
- Where the science stands: Public profile: 0 PubMed studies, 0 human trials (Anecdotal). OHM’s internal 0035 grading cites manufacturer topical RCTs (~10–30% wrinkle-depth reduction over 4–8 weeks, Lubrizol)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No specific adverse-effect data was captured in the source profile. As a topical-only cosmetic ingredient, the family-wide safety read applies: topical delivery has a benign safety record because it isn’t injected or absorbed systemically in meaningful amounts.
Regulatory status: Argireline is sold as a cosmetic-grade topical ingredient in commercial skincare formulations — legal OTC, not an FDA-reviewed drug and not a peptide sold through research-peptide channels.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Argireline is a topical-only ingredient. Typical cosmetic formulation is 5–10% in leave-on serums, per general cosmetic-industry convention. There is no injectable or systemic use case for this compound.
What should I avoid combining — and what's synergistic?
Argireline (acetyl Hexapeptide-3) doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
The original “topical Botox” peptide — decades of use in leave-on serums, a plausible SNARE-complex mechanism, and a public evidence record that’s thinner than the marketing. Honest read: real mechanism, gentle real-world effect, and the strongest efficacy numbers come from manufacturer trials, not independent PubMed RCTs.
| Class | Neuromuscular “Botox-like” relaxer — topical cosmetic peptide |
| Mechanism (one line) | Competes with SNAP-25 in the SNARE complex → less acetylcholine release at the neuromuscular junction → gentler muscle contraction |
| Evidence base | Public profile: 0 PubMed studies, 0 human trials (Anecdotal). OHM’s internal 0035 grading cites manufacturer topical RCTs (~10–30% wrinkle-depth reduction over 4–8 weeks, Lubrizol) |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Argireline is the best-known and longest-marketed of the “topical Botox” peptide family — a hexapeptide formulated into serums and creams as a topical alternative to injectable neuromodulators for softening expression lines (forehead lines, crow’s feet, frown lines).
How it works
Argireline competes with SNAP-25 for its position in the SNARE complex, the molecular machinery that docks neurotransmitter vesicles at the neuromuscular junction. By displacing SNAP-25, it reduces vesicle docking and acetylcholine release, so the muscle contracts less intensely — the same target signal that botulinum toxin blocks at the muscle, approached from a topical serum instead of an injection.
What the research shows
The public record and OHM’s internal grading tell two different stories, and both are worth knowing:
- Public profile: zero PubMed-indexed studies and zero human trials — graded Anecdotal.
- OHM’s 0035 categorization pass graded Argireline Tier C / green and recommend-eligible, on the basis of “small human topical RCTs in wrinkle-depth reduction (~10–30% on facial wrinkles over 4–8 weeks)” attributed to manufacturer (Lubrizol) research.
That gap — real formulator data that doesn’t show up in the independent PubMed record — is itself the honest story here: the evidence likely exists, but it’s largely industry-held rather than independently published.
Real-world protocol
Argireline is a topical-only ingredient. Typical cosmetic formulation is 5–10% in leave-on serums, per general cosmetic-industry convention. There is no injectable or systemic use case for this compound.
Side effects & management
No specific adverse-effect data was captured in the source profile. As a topical-only cosmetic ingredient, the family-wide safety read applies: topical delivery has a benign safety record because it isn’t injected or absorbed systemically in meaningful amounts.
Regulatory status
Argireline is sold as a cosmetic-grade topical ingredient in commercial skincare formulations — legal OTC, not an FDA-reviewed drug and not a peptide sold through research-peptide channels.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing manufacturer (Lubrizol) topical RCTs.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: SNAP-8 · Vialox · Syn-Ake · Pentapeptide-18
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing manufacturer (Lubrizol) topical RCTs.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: SNAP-8 · Vialox · Syn-Ake · Pentapeptide-18